Literature DB >> 27093862

Length of Endoprosthetic Reconstruction in Revision Knee Arthroplasty Is Associated With Complications and Reoperations.

Jeffrey J Barry1, Zachary Thielen1, David C Sing1, Paul H Yi1, Erik N Hansen1, Michael Ries2.   

Abstract

BACKGROUND: Complex revision total knee arthroplasty (TKA) often calls for endoprosthetic reconstruction to address bone loss, poor bone quality, and soft tissue insufficiency. Larger amounts of segmental bone loss in the setting of joint replacement may be associated with greater areas of devascularized tissue, which could increase the risk of complications and worsen functional results. QUESTIONS/PURPOSES: Are longer endoprosthetic reconstructions associated with (1) higher risk of deep infection; (2) increased risk of reoperation and decreased implant survivorship; or (3) poorer ambulatory status?
METHODS: This is a single-institution retrospective case series of nononcologic femoral endoprosthetic reconstructions for revision TKA from 1995 to 2013 (n = 32). Cases were categorized as distal (n = 17) or diaphyseal (n = 15) femoral reconstructions based on extension to or above the supracondylar metaphyseal-diaphyseal junction, respectively. Five patients from each group were lost to followup before 2 years (distal mean 4 years [range, 2-8 years]; diaphyseal mean = 6 years [range, 2-16 years]), and one of the 12 distal reconstructions and two of the 10 diaphyseal reconstructions had not been evaluated within the past 5 years. Clinical outcomes and ambulatory status (able to walk or not) were assessed through chart review by authors not involved in any cases. Prior incidence of periprosthetic joint infection was high in both groups (distal = seven of 12 versus diaphyseal = four of 10; p = 0.670).
RESULTS: Patients with diaphyseal femoral replacements were more likely to develop postoperative deep infections than patients with distal femoral replacements (distal = three of 12 versus diaphyseal = nine of 10; p = 0.004). Implant survivorship (revision-free) for diaphyseal reconstructions was worse at 2 years (distal = 100%, 95% confidence interval [CI], 100%-100% versus diaphyseal = 40%, 95% CI, 19%-86%; p = 0.001) and 5 years (distal = 90%, 95% CI, 75%-100% versus diaphyseal = 30%, 95% CI, 12%-73%; p = 0.001). Infection-free, revision-free survival (retention AND no infection) was worse for diaphyseal femoral replacing reconstructions than for distal femoral replacements at 2 years (distal = 70%, 95% CI, 48%-100% versus diaphyseal = 20%, 95% CI, 6%-69%; p = 0.037) and 5 years (distal = 70%, 95% CI, 48%-100% versus diaphyseal = 10%, 95% CI, 2%-64%; p = 0.012). There was no difference with the small numbers available in proportion of patients able to walk (distal reconstruction = eight of 11 versus diaphyseal = seven of 10; p = 1.000), although all but one patient in each group required walking aids.
CONCLUSIONS: Endoprosthetic femoral reconstruction is a viable salvage alternative to amputation for treatment of failed TKA with segmental distal femoral bone loss. In our small series even with substantial loss to followup and likely best-case estimates of success, extension proximal to the supracondylar metaphyseal-diaphyseal junction results in higher infection and revision risk. In infection, limb salvage remains possible with chronic antibiotic suppression, which we now use routinely for all femoral replacement extending into the diaphysis. LEVEL OF EVIDENCE: Level III, therapeutic study.

Entities:  

Mesh:

Year:  2017        PMID: 27093862      PMCID: PMC5174028          DOI: 10.1007/s11999-016-4836-x

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  22 in total

1.  Total knee arthroplasty for salvage of failed internal fixation or nonunion of the distal femur.

Authors:  George J Haidukewych; Bryan D Springer; David J Jacofsky; Daniel J Berry
Journal:  J Arthroplasty       Date:  2005-04       Impact factor: 4.757

2.  Revision arthroplasty with use of a total femur prosthesis.

Authors:  C Friesecke; J Plutat; A Block
Journal:  J Bone Joint Surg Am       Date:  2005-12       Impact factor: 5.284

3.  Distal femur replacement is useful in complex total knee arthroplasty revisions.

Authors:  Richard J Harrison; Mihir M Thacker; J David Pitcher; H Thomas Temple; Sean P Scully
Journal:  Clin Orthop Relat Res       Date:  2006-05       Impact factor: 4.176

4.  Intramedullary total femoral replacement for salvage of the compromised femur associated with hip and knee arthroplasty.

Authors:  Christopher L Peters; Joshua M Hickman; Jill Erickson; Adolph V Lombardi; Keith R Berend; Thomas H Mallory
Journal:  J Arthroplasty       Date:  2006-01       Impact factor: 4.757

5.  Survival of current production tumor endoprostheses: complications, functional results, and a comparative statistical analysis.

Authors:  E Pala; E R Henderson; T Calabrò; A Angelini; C N Abati; G Trovarelli; P Ruggieri
Journal:  J Surg Oncol       Date:  2013-09-04       Impact factor: 3.454

6.  Comparison of mechanical and nonmechanical failure rates associated with rotating hinged total knee arthroplasty in nontumor patients.

Authors:  Travis H Smith; Bishoy V Gad; Alison K Klika; Joseph F Styron; Timothy A Joyce; Wael K Barsoum
Journal:  J Arthroplasty       Date:  2013-01       Impact factor: 4.757

7.  Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study.

Authors:  H Wafa; R J Grimer; K Reddy; L Jeys; A Abudu; S R Carter; R M Tillman
Journal:  Bone Joint J       Date:  2015-02       Impact factor: 5.082

8.  Supracondylar distal femoral nonunions treated with a megaprosthesis in elderly patients: a report of two cases.

Authors:  J Davila; A Malkani; J M Paiso
Journal:  J Orthop Trauma       Date:  2001-11       Impact factor: 2.512

9.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

10.  Distal femoral replacement in nontumor cases with severe bone loss and instability.

Authors:  Keith R Berend; Adolph V Lombardi
Journal:  Clin Orthop Relat Res       Date:  2008-06-04       Impact factor: 4.176

View more
  6 in total

1.  Is the revision of a primary TKA really as easy and safe as the revision of a primary UKA?

Authors:  Kevin Staats; Christian Merle; Tom Schmidt-Braekling; Friedrich Boettner; Reinhard Windhager; Wenzel Waldstein
Journal:  Ann Transl Med       Date:  2016-12

2.  Proximal femoral replacement in non-oncologic patients undergoing revision total hip arthroplasty.

Authors:  Ivan De Martino; Rocco D'Apolito; Allina A Nocon; Thomas P Sculco; Peter K Sculco; Mathias P Bostrom
Journal:  Int Orthop       Date:  2018-11-10       Impact factor: 3.075

3.  Hot spots and trends in knee revision research since the 21st century: a bibliometric analysis.

Authors:  Kelei Zhai; Weifeng Ma; Tao Huang
Journal:  Ann Transl Med       Date:  2021-03

4.  REVIEW OF TOTAL KNEE ARTHROPLASTY AND THE BRAZILIAN UNIFIED HEALTH SYSTEM: A NATIONAL PROBLEM.

Authors:  Lucas da Ponte Melo; Guilherme Augusto Losso; Guilherme Henrique Ricardo da Costa; José Ricardo Pécora; Marco Kawamura Demange; Camilo Partezani Helito
Journal:  Acta Ortop Bras       Date:  2019 Sep-Oct       Impact factor: 0.513

5.  Bone Defects in Revision Total Knee Arthroplasty.

Authors:  Alan de Paula Mozella; Hugo Alexandre de Araújo Barros Cobra
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2020-09-25

6.  Revision TKA with a distal femoral replacement is at high risk of reinfection after two-stage exchange for periprosthetic knee joint infection.

Authors:  Jan Schwarze; Burkhard Moellenbeck; Christoph Theil; Kristian Nikolaus Schneider; Georg Gosheger; Tom Schmidt-Braekling; Thomas Ackmann; Ralf Dieckmann; Adrien Frommer; Sebastian Klingebiel
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-02-10       Impact factor: 4.342

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.